A Sweeping New AI to Detect Heart Conditions Is Coming to OpenEvidence
A new artificial-intelligence tool can now read a routine 12-lead electrocardiogram and flag structural heart disease that the human eye typically misses.
The tool, called EchoNext, was built by Pathway Labs using ECG-echocardiogram pairs originally developed at NewYork-Presbyterian and Columbia University.
It just received the world's first FDA clearance for multicondition AI detection in cardiology, covering six structural heart conditions.
Perhaps more importantly for everyday practice, EchoNext is now being deployed inside OpenEvidence, the clinical decision-support platform already used by roughly half of practicing U.S. physicians.
That distribution strategy, rather than the algorithm itself, may be what changes daily practice fastest.
What EchoNext Actually Detects
The model screens for six categories of disease that ordinary ECG interpretation cannot reliably catch: right-sided heart failure, left-sided heart failure, valve disease, severe hypertrophy consistent with infiltrative cardiomyopathy, pulmonary hypertension, and broader structural or congenital abnormalities.
All of these conditions share a common problem: they are common, often silent, and usually diagnosed only after a patient becomes symptomatic or develops overt heart failure.
The standard 12-lead ECG is inexpensive, fast, and already ordered millions of times per year, which is exactly why a screening layer built on top of it is attractive.
Unlike echocardiography, the ECG requires no sonographer, no scheduling delay, and no incremental imaging cost.
Detection rate of structural heart disease in a head-to-head validation study
In a head-to-head validation, EchoNext identified 77% of structural heart problems, compared with 64% for cardiologists reading the same tracings unaided.
The model was trained on more than 700,000 paired ECGs and echocardiograms, then externally validated across more than 20 hospitals and 500,000 patients.
A peer-reviewed report in Nature Medicine described the first documented case in which EchoNext flagged previously undiagnosed heart failure that ultimately led to a heart transplant.
Why Distribution Through OpenEvidence Matters
An FDA clearance that sits unused inside a single health system changes very little for the average outpatient cardiologist or internist.
By embedding EchoNext directly into OpenEvidence, Pathway Labs is effectively skipping years of piecemeal hospital-by-hospital implementation.
Workflow-wise, a clinician will be able to upload an image of an ECG into the platform and receive an algorithmic structural-disease risk prediction in return.
That puts a screening capability previously confined to research-grade academic centers into community clinics, urgent cares, and small cardiology practices.
The Six Cleared Indications at a Glance
| Condition Flagged | Clinical Relevance |
|---|---|
| Left-sided heart failure | Often subclinical until exertional symptoms develop |
| Right-sided heart failure | Frequently under-recognized on routine exam |
| Valve disease | May precede audible murmur or symptom onset |
| Severe hypertrophy / infiltrative cardiomyopathy pattern | Raises suspicion for conditions such as amyloidosis or hypertrophic cardiomyopathy |
| Pulmonary hypertension | Commonly diagnosed late, after right-heart strain develops |
| Other structural / congenital abnormality | Captures residual structural disease outside the above categories |
Company and Platform Snapshot
| Entity | Role | Ownership Status |
|---|---|---|
| Pathway Labs | Developer of EchoNext algorithm | Privately held; no public ticker |
| OpenEvidence | Clinical decision-support distribution platform | Privately held; no public ticker |
Pathway Labs also disclosed an $8.5 million seed financing round led by AlleyCorp and Breyer Capital to fund health-system expansion, clinical team growth, and continued research.
Neither company is publicly traded, so there are no equity tickers or per-test consumer pricing to report at this time.
For physician-investors tracking the AI-in-cardiology space more broadly, exposure currently runs through diversified healthcare-technology vehicles rather than single-name positions in this particular tool.
Practical Considerations Before Adoption
EchoNext is a screening aid, not a diagnostic replacement for echocardiography.
A flagged result should prompt confirmatory imaging rather than a standalone clinical decision.
Reimbursement and CPT coding pathways for AI-augmented ECG interpretation remain unsettled and should be clarified with billing compliance before routine use.
Documentation should clearly distinguish an AI-generated screening flag from a formal cardiologist interpretation to avoid medicolegal ambiguity.
A 58-year-old patient presents to a primary care clinic for an annual physical with no cardiac complaints.
A routine ECG is obtained and uploaded into the practice's clinical decision-support platform.
The AI screening tool flags a pattern consistent with severe hypertrophy and possible infiltrative cardiomyopathy.
The patient is referred for echocardiography and subsequent cardiac MRI, which confirm early transthyretin amyloid cardiomyopathy at a stage when targeted therapy can still meaningfully alter the disease course.
EchoNext brings FDA-cleared, AI-driven structural heart disease screening to the most commonly ordered cardiac test in medicine.
Its integration into a decision-support platform used by roughly half of U.S. physicians could extend early detection capability well beyond academic cardiology centers.
Confirmatory imaging, clear documentation, and attention to billing pathways will remain essential as adoption spreads.
References
- Medical Economics: FDA-cleared AI tool flags hidden heart disease from a standard ECG
- Pathway Labs' EchoNext Receives World's First FDA Clearance
- TechTarget: OpenEvidence brings AI-powered heart disease detection to doctors
- NewYork-Presbyterian: AI tool to detect hidden heart disease receives FDA approval
- STAT News: AI tool turns EKGs into predictions of structural heart disease
- Business Wire: Pathway Labs Announces World's First FDA Clearance for Multicondition AI in Cardiology
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.